"The agreement is a good strategic fit," said QIAGEN's CEO Peer Schatz. "It has the potential to significantly accelerate our dissemination strategy for the QIAsymphony RGQ by expanding our molecular diagnostic menu offering in the United States with important testing options. It also allows us to commercialize previously unused intellectual property around a PCR design for HPV assays by converting it into revenue and by targeting it into a clearly defined sub-segment of the market. And, finally, it enables both parties to address the different market segments for HPV and thereby promises to further drive market adoption of this important testing method in North America."
"We're pleased to provide QIAGEN access to our leading technology, and believe the addition of a PCR-based HPV test to our m2000 menu will benefit many more women who may be infected with the virus and at risk of developing cervical cancer," said Stafford O'Kelly, head of Abbott's molecular diagnostics business.
QIAGEN's portfolio already includes a broad menu of assays including FDA
approved assays for HPV (digene HPV) and chlamydia as well as CE-labeled
tests for the detection of HIV, HCV, hepatitis B virus (HBV), cytomegalovirus
(CMV), Epstein-Barr virus (EBV), herpes-simplex virus (HSV), Influenza,
multiple bacteria and respiratory viruses, personalized healthcare assays
such as KRAS, EGFR, as well as many other target diseases. In addition,
QIAGEN has a broad pipeline of additional and novel assays for its
QIAsymphony and QIAensemble platforms for launch in the U.S., Europe and in
many other countries
Copyright©2010 PR Newswire.
All rights reserved